138 related articles for article (PubMed ID: 18469157)
1. Cyclooxygenase-2 predicts adverse effects of tamoxifen: a possible mechanism of role for nuclear HER2 in breast cancer patients.
Dillon MF; Stafford AT; Kelly G; Redmond AM; McIlroy M; Crotty TB; McDermott E; Hill AD; Young LS
Endocr Relat Cancer; 2008 Sep; 15(3):745-53. PubMed ID: 18469157
[TBL] [Abstract][Full Text] [Related]
2. Activated ERK1/2 and phosphorylated oestrogen receptor alpha are associated with improved breast cancer survival in women treated with tamoxifen.
Bergqvist J; Elmberger G; Ohd J; Linderholm B; Bjohle J; Hellborg H; Nordgren H; Borg AL; Skoog L; Bergh J
Eur J Cancer; 2006 May; 42(8):1104-12. PubMed ID: 16603346
[TBL] [Abstract][Full Text] [Related]
3. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
[TBL] [Abstract][Full Text] [Related]
4. Expression of HER2 and its association with AP-2 in breast cancer.
Pellikainen J; Naukkarinen A; Ropponen K; Rummukainen J; Kataja V; Kellokoski J; Eskelinen M; Kosma VM
Eur J Cancer; 2004 Jul; 40(10):1485-95. PubMed ID: 15196531
[TBL] [Abstract][Full Text] [Related]
5. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma.
Denkert C; Winzer KJ; Müller BM; Weichert W; Pest S; Köbel M; Kristiansen G; Reles A; Siegert A; Guski H; Hauptmann S
Cancer; 2003 Jun; 97(12):2978-87. PubMed ID: 12784332
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
[TBL] [Abstract][Full Text] [Related]
7. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
[TBL] [Abstract][Full Text] [Related]
8. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.
Fujii T; Kawahara A; Basaki Y; Hattori S; Nakashima K; Nakano K; Shirouzu K; Kohno K; Yanagawa T; Yamana H; Nishio K; Ono M; Kuwano M; Kage M
Cancer Res; 2008 Mar; 68(5):1504-12. PubMed ID: 18316615
[TBL] [Abstract][Full Text] [Related]
9. Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1.
Fleming FJ; Myers E; Kelly G; Crotty TB; McDermott EW; O'Higgins NJ; Hill AD; Young LS
J Clin Pathol; 2004 Oct; 57(10):1069-74. PubMed ID: 15452162
[TBL] [Abstract][Full Text] [Related]
10. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
11. Cox-2 and Her2/neu co-expression in invasive bladder cancer.
Eltze E; Wülfing C; Von Struensee D; Piechota H; Buerger H; Hertle L
Int J Oncol; 2005 Jun; 26(6):1525-31. PubMed ID: 15870865
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer.
Borgquist S; Jögi A; Pontén F; Rydén L; Brennan DJ; Jirström K
Breast Cancer Res; 2008; 10(5):R79. PubMed ID: 18808688
[TBL] [Abstract][Full Text] [Related]
13. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
[TBL] [Abstract][Full Text] [Related]
14. p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer.
Yamashita H; Toyama T; Nishio M; Ando Y; Hamaguchi M; Zhang Z; Kobayashi S; Fujii Y; Iwase H
Breast Cancer Res; 2006; 8(4):R48. PubMed ID: 16869955
[TBL] [Abstract][Full Text] [Related]
15. A positive role for PEA3 in HER2-mediated breast tumour progression.
Myers E; Hill AD; Kelly G; McDermott EW; O'Higgins NJ; Young LS
Br J Cancer; 2006 Nov; 95(10):1404-9. PubMed ID: 17060941
[TBL] [Abstract][Full Text] [Related]
16. Biological profile of oestrogen receptor positive primary breast cancers in the elderly and response to primary endocrine therapy.
Okunade G; Green AR; Ying M; Agrawal A; Paish EC; Aleskandrany M; Winterbottom L; Hassell K; Morgan DA; Ellis IO; Cheung KL
Crit Rev Oncol Hematol; 2009 Oct; 72(1):76-82. PubMed ID: 19515574
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer.
Holm C; Kok M; Michalides R; Fles R; Koornstra RH; Wesseling J; Hauptmann M; Neefjes J; Peterse JL; Stål O; Landberg G; Linn SC
J Pathol; 2009 Feb; 217(3):372-9. PubMed ID: 18991335
[TBL] [Abstract][Full Text] [Related]
18. Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome.
Zerkowski MP; Camp RL; Burtness BA; Rimm DL; Chung GG
Cancer Invest; 2007 Feb; 25(1):19-26. PubMed ID: 17364553
[TBL] [Abstract][Full Text] [Related]
19. ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis.
Svensson S; Jirström K; Rydén L; Roos G; Emdin S; Ostrowski MC; Landberg G
Oncogene; 2005 Jun; 24(27):4370-9. PubMed ID: 15806151
[TBL] [Abstract][Full Text] [Related]
20. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E
Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]